WASHINGTON, D.C. — Sens. Orrin Hatch and Sheldon Whitehouse recently introduced two bills to streamline the drug development process and protect patient access to needed medications. The bills are titled the Improving Regulatory Transparency for New Medical Therapies Act and the Ensuring Patient Access and Effective Drug Enforcement Act of 2015.

The bipartisan legislation streamlines and increases transparency in the approval process for drugs that fall under the Controlled Substances Act, also referred to as CSA, by creating a specific timeline for the Drug Enforcement Administration to schedule certain controlled substances.  The bill also clarifies terminology in the CSA to improve DEA’s ability to work collaboratively with distributors and other stakeholders to prevent drug diversion.

“Patients can greatly benefit from a modernized, effective approval process for new therapies,” Hatch said. “These common-sense pieces of legislation place a greater emphasis on transparency and timeliness while preserving DEA’s authority to prevent unsafe therapies from entering the supply chain.”

Improving Regulatory Transparency for New Medical Therapies Act

The bill improves incentives for medical innovation by amending the Federal Food, Drug, and Cosmetic Act and the Controlled Substances Act to require the Drug Enforcement Agency to schedule a drug or substance that has never been marketed in the United States within 45 days of receiving a scheduling recommendation from the Secretary of HHS.

It also speeds the development of new therapies by allowing researchers to indicate on their DEA application that the controlled substance will only be used for clinical trials of a drug.

“Giving patients timely access to treatments and ensuring that prescription drugs don’t fall into the wrong hands are important goals, and I’m glad to be working with Senator Hatch to craft legislation to help,” said Whitehouse.

See the bill here: Improving Regulatory Transparency for New Medical Therapies Act

Ensuring Patient Access and Effective Drug Enforcement Act of 2015

The bill clarifies terminology in the CSA for the terms “consistent with the public health and safety” and “imminent danger” to improve the ability of the DEA to work collaboratively with distributors and other stakeholders to prevent drug diversion.

It also allows CSA registrants who face having their registration revoked or suspended to submit a corrective action plan.

The bill requires the Secretary of Health and Human Services and Administrator of the Drug Enforcement Administration to submit a report to Congress assessing how enforcement activities may impact patient access and identify how collaboration between agencies and stakeholders can benefit patients and prevent prescription drug abuse.

See the bill here: Ensuring Patient Access and Effective Drug Enforcement Act of 2015

Submitted by the Offices of Sen. Orrin Hatch

Related posts

• Drug-free zones: What, where are they? What is their purpose? STGnews Videocast
• On the EDge: Congress and its drug money addiction
• Hatch, Bennet reintroduce PATH Act to streamline approval of antibiotics

Email: [email protected]

Twitter: @STGnews